Effect of sodium-glucose cotransporter 2 inhibitor combined with sacubitril/valsartan on chronic heart failure with type 2 diabetes
Objective To observe the effect of sodium glucose cotransporter 2(SGLT2)inhibitor combined with sacubitril/valsartan on vascular endothelial function and major adverse cardiovascular events(MACE)in patients with chronic heart failure(CHF)and type 2 diabetes mellitus(T2DM).Methods A total of 156 patients with CHF and T2DM who were admitted to the hospital were selected,and divided into combination group and control group by random number table method,78 cases in each group.On the basis of conventional treatment,the control group was treated with sacubitril/valsartan,while the combination group was treated with SGLT2 inhibitor combined with sacubitril/valsartan.The clinical effect,vascular endothelial function indicators,blood glucose,cardiac function indicators,and the incidence of MACE during treatment were compared between the groups.Results After treatment,the clinical efficacy of the combined group was 89.74%,higher than 75.64%of the control group(P<0.05),and the calcitoningene related peptide(CGRP),left ventricular ejection fraction(LVEF)and stroke volume(SV)levels in the combined group were significantly higher than those in the control group,while resistin,endothelin-1(ET-1),fasting plasma glucose(FPG),glucosylated hemoglobin(HbAlc),left ventricular end-systolic dimension(LVESD),left ventricular end-diastolic dimension(LVEDD)levels and the total incidence of MACE in the combined group were lower than those in the control group(P<0.05).Conclusion SGLT2 inhibitor combined with sacubitril/valsartan is effective in the treatment of CHF complicated with T2DM,which can significantly improve the patients'vascular endothelial function,blood glucose and cardiac function,and reduce the incidence of MACE.
万方数据
维普
